PI of The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,China🎓
Dr. Run-Ze Li has made substantial contributions to integrative medicine and oncology research, specializing in innovative antitumor therapies. His research focuses on utilizing immune metabolism as a pathway for early diagnosis and targeted treatment of lung cancer. Over the past few years, Dr. Li has led several significant projects (national, provincial, and municipal levels) and published extensively, with 37 SCI-indexed journal papers, including contributions to Nature Communications and other high-impact journals. He has also been recognized with prestigious awards and holds several editorial positions, underscoring his leadership in the field.
Professional Profile
Education 🎓:
🎓 Dr. Li received his Doctorate from the Macau University of Science and Technology, where he developed a foundation in Traditional Chinese Medicine (TCM) and integrative healthcare. This education has guided his innovative approaches to integrating traditional Chinese and Western medicine in antitumor drug research.
Work Experience 💼:
🔬 Over the last few years, Dr. Li has overseen multiple high-impact research projects, including three national, four provincial, and two municipal projects. His extensive research has contributed significantly to clinical advancements in oncology, including his work on antitumor drug development, specifically focused on immune metabolism and biomarker discovery.
Skills 🔍
Innovative Cancer Researcher | Project Leadership | Data Analysis & AI-Driven Biomarker Discovery | Scientific Publication and Editing
Dr. Li’s expertise lies in the application of artificial intelligence for biomarker identification, immune metabolism in oncology, and development of clinical models for lung cancer.
Awards and Honors 🏆
🏆 Dr. Li has earned multiple accolades, including the Excellent Graduate Supervisor Award from Guangzhou University of Chinese Medicine, in recognition of his mentorship and research contributions. He has also published in high-impact journals like Nature Communications, with a total of 37 SCI-indexed publications and 342 citations.
🤝 Memberships:
👥 Dr. Li holds editorial positions as Section Editor for Heliyon-Cancer Research and Associate Editor for Ageing and Cancer Research & Treatment, among other roles. He is also a member of the Youth Editorial Board of Engineering, reflecting his leadership in the field.
Teaching Experience 👩🏫:
📚 Dr. Li actively mentors graduate students and oversees TCM-integrated research projects, providing guidance in the intersection of clinical applications and innovative drug research. He is known for his dedication to shaping the next generation of TCM researchers.
Research Focus 🔬:
🔍 Dr. Li’s primary research direction centers on integrative medicine for antitumor drug development, particularly targeting immune metabolism for lung cancer diagnosis and treatment. His team has developed a pioneering in vivo model to study immune responses in lung cancer, opening pathways for new therapeutic strategies and targeted drug interventions.
📚 Publilcation
- “Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice”
- Year: 2024
- Journal: Frontiers in Immunology
- Authors: Ma, G., Xu, Z., Li, C., Li, R., Liu, L.
- “Serum taurine affects lung cancer progression by regulating tumor immune escape mediated by the immune microenvironment”
- Year: 2024
- Journal: Journal of Advanced Research
- Authors: Liang, T.-L., Pan, H.-D., Yan, P.-Y., Liu, L., Li, R.-Z.
- “Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy”
- Year: 2023
- Journal: Nature Communications
- Authors: Leung, E.L.-H., Li, R.-Z., Fan, X.-X., Cao, Y., Liu, L.
- Erratum: “Author correction to ‘Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice”
- Year: 2023
- Journal: Acta Pharmaceutica Sinica B
- Authors: Fan, X., Mai, C., Zuo, L., Xie, Y., Lai-Han Leung, E.
- “CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer”
- Year: 2023
- Journal: Pharmacological Research
- Authors: Wang, J., Li, R.-Z., Wang, W.-J., He, J.-X., Leung, E.L.-H.
- “Myricetin possesses the potency against SARS-CoV-2 infection through blocking viral-entry facilitators and suppressing inflammation in rats and mice”
- Year: 2023
- Journal: Phytomedicine
- Authors: Pan, H., He, J., Yang, Z., Li, R.-Z., Liu, L.
- “Sinomenine hydrochloride bidirectionally inhibits progression of tumor and autoimmune diseases by regulating AMPK pathway”
- Year: 2023
- Journal: Phytomedicine
- Authors: Li, R.Z., Guan, X.X., Wang, X.R., Pan, H.-D., Liu, L.
- “The longitudinal and regional analysis of bleomycin-induced pulmonary fibrosis in mice by microcomputed tomography”
- Year: 2023
- Journal: Heliyon
- Authors: Lai, R., Zhao, C., Guo, W., Liu, L., Pan, H.
- “Combinational study with network pharmacology, molecular docking and preliminary experiments on exploring common mechanisms underlying the effects of weijing decoction on various pulmonary diseases”
- Year: 2023
- Journal: Heliyon
- Authors: Li, J.-X., Han, Z.-X., Cheng, X., Tang, L., Yang, J.-S.
- “Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice”
- Year: 2023
- Journal: Acta Pharmaceutica Sinica B
- Authors: Fan, X., Mai, C., Zuo, L., Xie, Y., Leung, E.L.-H.